Skip to main content
Top
Published in: International Journal of Hematology 2/2021

01-08-2021 | Acute Lymphoblastic Leukemia | Case Report

ETV6-related thrombocytopenia associated with a transient decrease in von Willebrand factor

Authors: Yuri Kanamaru, Toru Uchiyama, Tadashi Kaname, Kumiko Yanagi, Osamu Ohara, Shinji Kunishima, Akira Ishiguro

Published in: International Journal of Hematology | Issue 2/2021

Login to get access

Abstract

ETV6-related thrombocytopenia is an autosomal dominant thrombocytopenia, characterized by a bleeding tendency and predisposition to hematological malignancies. The similarity in symptoms makes differentiating immune and congenital thrombocytopenia challenging. We report a 5-year-old girl who presented with chronic thrombocytopenia associated with repetitive and long-lasting epistaxis, leading to blood transfusion for severe anemia. Blood tests showed thrombocytopenia (52 × 103/µL) with normal-sized platelets and transiently low von Willebrand factor (VWF) levels (VWF:RCo 13%, VWF:Ag 50%); therefore, von Willebrand disease type 2 was initially suspected. Repetition of the blood tests revealed normal levels of VWF. Exome and Sanger sequencing identified a germline ETV6 heterozygous variant, c.641C > T:p.(P214L). No additional pathogenic variants were found, including VWF, in the gene panel testing of the 53 known target causative genes for thrombocytopenia. High-throughput exome sequencing for chronic thrombocytopenia can be utilized to differentially diagnose ETV6-related thrombocytopenia from chronic/intractable immune thrombocytopenia and to effectively monitor malignancy.
Literature
1.
go back to reference Poggi M, Canault M, Favier M, Turro E, Saultier P, Ghalloussi D, et al. Germline variants in ETV6 underlie reduced platelet formation, platelet dysfunction and increased levels of circulation CD34+ progenitors. Haematologica. 2017;102:282–94.CrossRef Poggi M, Canault M, Favier M, Turro E, Saultier P, Ghalloussi D, et al. Germline variants in ETV6 underlie reduced platelet formation, platelet dysfunction and increased levels of circulation CD34+ progenitors. Haematologica. 2017;102:282–94.CrossRef
2.
go back to reference Noetzli L, Lo RW, Lee-Sherick AB, Callaghan M, Noris P, Savioa A, et al. Germline mutations in ETV6 are associated with thrombocytopenia, red cell macrocytosis and predisposition to lymphoblastic leukemia. Nat Genet. 2015;47:535–8.CrossRef Noetzli L, Lo RW, Lee-Sherick AB, Callaghan M, Noris P, Savioa A, et al. Germline mutations in ETV6 are associated with thrombocytopenia, red cell macrocytosis and predisposition to lymphoblastic leukemia. Nat Genet. 2015;47:535–8.CrossRef
3.
go back to reference Moriyama T, Metzger ML, Wu G, Nishii R, Qian M, Devidas M, et al. Germline genetic variation in ETV6 and risk of childhood acute lymphoblastic leukemia: a systematic genetic study. Lancet Oncol. 2015;16:1659–66.CrossRef Moriyama T, Metzger ML, Wu G, Nishii R, Qian M, Devidas M, et al. Germline genetic variation in ETV6 and risk of childhood acute lymphoblastic leukemia: a systematic genetic study. Lancet Oncol. 2015;16:1659–66.CrossRef
4.
go back to reference Melazzini F, Palombo F, Balduini A, De Rocco D, Marconi C, Noris P, et al. Clinical and pathogenic features of ETV6-related thrombocytopenia with predisposition to acute lymphoblastic leukemia. Haematologica. 2016;101:1333–42.CrossRef Melazzini F, Palombo F, Balduini A, De Rocco D, Marconi C, Noris P, et al. Clinical and pathogenic features of ETV6-related thrombocytopenia with predisposition to acute lymphoblastic leukemia. Haematologica. 2016;101:1333–42.CrossRef
5.
go back to reference Di Paola J, Porter CC. ETV6-related thrombocytopenia and leukemia predisposition. Blood. 2019;134:663–7.CrossRef Di Paola J, Porter CC. ETV6-related thrombocytopenia and leukemia predisposition. Blood. 2019;134:663–7.CrossRef
6.
go back to reference Rodeghiero F, Tosetto A, Abshire T, Arnold DM, Coller B, James P, et al. ISTH/SCC bleeding assessment tool: a standardized questionnaire and a proposal for a new bleeding score for inherited bleeding disorders. J Thromb Haemost. 2010;8:2063–5.CrossRef Rodeghiero F, Tosetto A, Abshire T, Arnold DM, Coller B, James P, et al. ISTH/SCC bleeding assessment tool: a standardized questionnaire and a proposal for a new bleeding score for inherited bleeding disorders. J Thromb Haemost. 2010;8:2063–5.CrossRef
7.
go back to reference Fujiki R, Ikeda M, Yoshida A, Maeda A, Yao Y, Nishimura A, et al. Assessing the accuracy of variant detection in cost-effective gene panel testing by next-generation sequencing. J Mol Diagn. 2018;20:572–82.CrossRef Fujiki R, Ikeda M, Yoshida A, Maeda A, Yao Y, Nishimura A, et al. Assessing the accuracy of variant detection in cost-effective gene panel testing by next-generation sequencing. J Mol Diagn. 2018;20:572–82.CrossRef
8.
go back to reference Zhang MY, Churpek JE, Keel SB, Walsh T, Lee MK, Loeb KR, et al. Germline ETV6 mutations in familial thrombocytopenia and hematologic malignancy. Nat Genet. 2015;47:180–5.CrossRef Zhang MY, Churpek JE, Keel SB, Walsh T, Lee MK, Loeb KR, et al. Germline ETV6 mutations in familial thrombocytopenia and hematologic malignancy. Nat Genet. 2015;47:180–5.CrossRef
9.
go back to reference Feurstein S, Godley LA. Germline ETV6 mutations and predisposition to hematological malignancies. Int J Hematol. 2017;106:189–95.CrossRef Feurstein S, Godley LA. Germline ETV6 mutations and predisposition to hematological malignancies. Int J Hematol. 2017;106:189–95.CrossRef
10.
go back to reference Lavin M, O’Donnell JS. How I treat low von Willebrand factor levels. Blood. 2019;133:795–804.CrossRef Lavin M, O’Donnell JS. How I treat low von Willebrand factor levels. Blood. 2019;133:795–804.CrossRef
11.
go back to reference Lavin M, Aguila S, Schneppenheim S, Dalton N, Jones KL, O’Sullivan JM, et al. Novel insights into the clinical phenotype and pathophysiology underlying low VWF levels. Blood. 2017;130:2344–53.CrossRef Lavin M, Aguila S, Schneppenheim S, Dalton N, Jones KL, O’Sullivan JM, et al. Novel insights into the clinical phenotype and pathophysiology underlying low VWF levels. Blood. 2017;130:2344–53.CrossRef
12.
go back to reference O’Donnell J, Boulton FE, Manning RA, Laffan MA. Amount of H antigen expressed on circulation von Willebrand factor is modified by ABO blood group genotype and is a major determinant of plasma von Willebrand factor antigen levels. Arterioscler Thromb Vasc Biol. 2002;22:335–41.CrossRef O’Donnell J, Boulton FE, Manning RA, Laffan MA. Amount of H antigen expressed on circulation von Willebrand factor is modified by ABO blood group genotype and is a major determinant of plasma von Willebrand factor antigen levels. Arterioscler Thromb Vasc Biol. 2002;22:335–41.CrossRef
Metadata
Title
ETV6-related thrombocytopenia associated with a transient decrease in von Willebrand factor
Authors
Yuri Kanamaru
Toru Uchiyama
Tadashi Kaname
Kumiko Yanagi
Osamu Ohara
Shinji Kunishima
Akira Ishiguro
Publication date
01-08-2021
Publisher
Springer Singapore
Published in
International Journal of Hematology / Issue 2/2021
Print ISSN: 0925-5710
Electronic ISSN: 1865-3774
DOI
https://doi.org/10.1007/s12185-021-03136-4

Other articles of this Issue 2/2021

International Journal of Hematology 2/2021 Go to the issue
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine